Factors influencing primary care physicians’ decision to order prostate-specific antigen (PSA) test for men without prostate cancer

References

• Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079–92.
   PubMed Web of Science ®Google Scholar
• Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007;41:456–77.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765–81.
   PubMed Web of Science ®Google Scholar
• Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001;58:417–24.
   PubMed Web of Science ®Google Scholar
• Payne H, Cornford P. Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol 2011;29:593–601. [Review].
   PubMed Web of Science ®Google Scholar
• Loeb S, Catalona WJ. Prostate-specific antigen screening: Pro. Curr Opin Urol 2010;20:185–8.
   PubMed Web of Science ®Google Scholar
• Grubb RL, 3rd, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008;102:1524–30.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Chen MH, Catalona WJ, Moul JW, Sun L, D’Amico AV. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 2009;73:659–64.
   PubMed Web of Science ®Google Scholar
• Socialstyrelsen. Nationella riktlinjer för prostatacancersjukvård – Medicinskt och hälsoekonomiskt faktadokument. 2007.
   Google Scholar
• Diefenbach PN, Ganz PA, Pawlow AJ, Guthrie D. Screening by the prostate-specific antigen test: What do the patients know?. J Cancer Educ 1996;11:39–44.
   PubMedGoogle Scholar
• Berglund G, Nilsson S, Nordin K. Intention to test for prostate cancer. Eur J Cancer 2005;41:990–7.
   PubMed Web of Science ®Google Scholar
• Haggerty J, Tudiver F, Brown JB, Herbert C, Ciampi A, Guibert R. Patients’ anxiety and expectations: How they influence family physicians’ decisions to order cancer screening tests. Can Fam Physician 2005;51:1658–9.
   PubMedGoogle Scholar
• Moran WP, Cohen SJ, Preisser JS, Wofford JL, Shelton BJ, McClatchey MW. Factors influencing use of the prostate-specific antigen screening test in primary care. Am J Manag Care 2000;6:315–24.
   PubMed Web of Science ®Google Scholar
• Edlefsen KL, Mandelson MT, McIntosh MW, Andersen MR, Wagner EH, Urban N. Prostate-specific antigen for prostate cancer screening. Do physician characteristics affect its use?. Am J Prev Med 1999;17:87–90.
   PubMed Web of Science ®Google Scholar
• Voss JD, Schectman JM. Prostate cancer screening practices and beliefs. J Gen Intern Med 2001;16:831–7.
   PubMed Web of Science ®Google Scholar
• Tudiver F, Guibert R, Haggerty J, Ciampi A, Medved W, Brown JB, et al. What influences family physicians’ cancer screening decisions when practice guidelines are unclear or conflicting?. J Fam Pract 2002;51:760.
   PubMed Web of Science ®Google Scholar
• Bunting PS, Goel V, Williams JI, Iscoe NA. Prostate-specific antigen testing in Ontario: Reasons for testing patients without diagnosed prostate cancer. Can Med Assoc J 1999;160:70–5.
   Web of Science ®Google Scholar
• Curran V, Solberg S, Mathews M, Church J, Buehler S, Wells J, et al. Prostate cancer screening attitudes and continuing education needs of primary care physicians. J Cancer Educ 2005;20:162–6.
   PubMed Web of Science ®Google Scholar
• Glanz KRB, Lewis FM. Health behavior and health education: Theory, research, and practice, 3rd ed. San Francisco, California: Jossey-Bass; 2002.
   Google Scholar
• Drummond FJ, Carsin AE, Sharp L, Comber H. Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: A national survey of general practitioners. BMC Fam Pract 2009;10:3.
   PubMed Web of Science ®Google Scholar
• Farwell WR, Linder JA, Jha AK. Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med 2007;167:2497–502.
   PubMedGoogle Scholar
• Stroud L, Ross LE, Rose SW. Formative evaluation of the prostate cancer screening practices of African-American physicians. J Natl Med Assoc 2006;98:1637–43.
   PubMed Web of Science ®Google Scholar
• Beaulac JA., Fry RN, Onysko J. Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada. Can J Public Health 2006;97:171–6.
   PubMed Web of Science ®Google Scholar
• Gormley GJ, Catney D, McCall JR, Reilly PM, Gavin AT. Prostate-specific antigen testing: Uncovering primary care influences. BJU Int 2006;98:996–1000.
   PubMed Web of Science ®Google Scholar
• Frosch DL, Kaplan RM, Felitti V. The evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test. J Gen Intern Med 2001;16:391–8.
   PubMed Web of Science ®Google Scholar
• Volk RJ, Cass AR, Spann SJ. A randomized controlled trial of shared decision making for prostate cancer screening. Arch Fam Med 1999;8:333–40.
   PubMedGoogle Scholar